David Grimm and Simon Goldman make the GUV Powerlist’s Top 25

Global University venturing today announced its GUV Powerlist Awards, which celebrates the top 100 leaders of university venture funds. The Fund’s two investment directors, David Grimm responsible for investments in the physical sciences space and Simon Goldman who manages investments for the biomedical sciences, both made the 16th place in the publication’s list. Read more from […]

Read more

Orchard Therapeutics announces closing of $225 Million Initial Public Offering

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has today announced closing of its initial public offering of 16,103,572 American Depositary Shares (“ADSs”), each representing an ordinary share at an initial public offering price of $14.00 per share. The gross proceeds from the offering were […]

Read more

Global University Venturing Interviews David Grimm

Global University Venturing editor Thierry Heles, recently interviewed UCLTF investment manager David Grimm to find out more about the uniqueness of the Fund and the role that it plays in supporting technologies arising from UCL’s knowledge base. Formed through a close collaboration between UCLB and Albion Capital, David explains how UCLTF was a long time […]

Read more

Gene therapy developer Orchard Therapeutics proposes IPO

Orchard Therapeutics Ltd. (London, U.K.) proposed to raise up to $172.5 million in an IPO on NASDAQ. J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow are underwriters. Orchard is developing autologous ex vivo lentiviral gene therapies to treat rare primary immune deficiencies and inherited metabolic disorders. In an April deal with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), […]

Read more

Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline

UCLTF funded Orchard Therapeutics, today announced the completion of an oversubscribed $150 million Series C financing. The biotechnology company is based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher at the UCL Institute of Child Health. The work of Orchard Therapeutics is dedicated to transforming the lives of patients with […]

Read more

UCL spin-out Hazy adds $1.8 million in seed funding

Funding led by the UCL Technology Fund with participation from Nationwide Building Society, Pentland, Amadeus Capital Partners and AI Seed Hazy, the London-based AI company enabling ethical, effortless and GDPR-compliant data sharing for responsible businesses, has announced an additional $1.8 million seed funding led by UCL Technology Fund, alongside Nationwide Building Society, Pentland, Amadeus Capital […]

Read more

UCL Technology Fund investment MeiraGTx raises $75m at IPO

UCL Technology Fund investment MeiraGTx Holdings plc (‘MeiraGTx’), the clinical stage gene therapy company, has raised $75million at IPO, pricing five million shares at $15.00 per share on the Nasdaq Global Select Market on June 12 2018. The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB), UCL’s commercialisation […]

Read more

Bloomsbury AI joins the Facebook Team in London

UCL Technology Fund is very proud to have backed Bloomsbury AI and we are delighted that they are joining the Facebook team in London. For the full story please follow the link below Bloomsbury AI joins the London Facebook Team

Read more